For personal use only

ASX Announcement
17 September 2026

Hydrix Secures Multi-Year A$0.625M Remote Cardiac Monitoring Contract with National Heart Centre Singapore

Hydrix Limited (ASX: HYD) is pleased to announce that its wholly owned subsidiary, Hydrix Medical Pty Ltd, has secured a multi-year contract with the National Heart Centre Singapore (NHCS) for the deployment of the Implicity™ cloud-based remote cardiac monitoring platform.

Highlights

- Multi-year contract with National Heart Centre Singapore (NHCS), one of Asia's leading cardiac hospitals
- Estimated contract value of approximately A$0.625 million over three years, subject to patient volumes monitored under the platform
- Annual recurring revenue approximately A$0.21 million over the agreed three-year term
- Establishes NHCS as a key reference customer to support further expansion opportunities

Under the agreement, NHCS will implement the Implicity platform to assist in the remote monitoring of patients with Cardiac Implantable Electronic Devices (CIEDs), including pacemakers, implantable cardioverter defibrillators (ICDs) and cardiac resynchronisation therapy devices.

The platform aggregates and standardises data from all major device manufacturers into a single interface, improving workflow efficiency for clinicians and supporting earlier intervention through advanced analytics.

Implementation of the platform is expected to commence shortly, with cloud deployment being delivered by Implicity and Hydrix Medical. Revenue flows to Hydrix upon implementation. Pricing and patient numbers are commercial-in-confidence.

For personal use only

Commentary

Arnaud Rosier, PhD, Chief Executive Officer of Implicity, said:

"We are delighted to see NHCS select the Implicity platform and are proud to continue our partnership with Hydrix Medical.

“This deployment supports our international growth strategy and reinforces the value that next-generation remote monitoring and AI-enabled cardiac care can deliver to leading healthcare institutions."

Vickie Edwards, Director Sales & Operations, Hydrix Medical, said:

"Securing National Heart Centre Singapore as a customer is a significant commercial milestone for Hydrix Medical and an important validation of our Asia-Pacific growth strategy.

“NHCS is recognised as one of the leading cardiovascular institutions in the region, and its selection of the Implicity platform demonstrates the growing need for scalable digital health solutions that improve operational efficiency while supporting better patient outcomes.

“We see NHCS as an important reference site as we pursue additional opportunities throughout Singapore, Australia and the broader Asia-Pacific region."

Ends ----

This announcement is authorised for release by the Board of Directors of Hydrix Limited.

For more information, please contact:

Hydrix Enquiries:	Media Enquiries:	Investor Enquiries:
Alan Morris	**Rod North**	**Niv Dagan**
Marketing Director	Managing Director	Executive Director
Hydrix Ltd	**Bourse Communications**	**Peak Asset Management**
alan.morris@hydrix.com	rod@boursecommunications.com.au	niv.dagan@peakassetmanagement.com.au
+61 3 9550 8100	+61 3 9510 8309	M 0402 912 198

For personal use only

About Hydrix Limited

Hydrix Limited (ASX: HYD) is an Australian technology company operating across medical technology, defence, industrial and mining. The Group combines multidisciplinary engineering, technology investment, intellectual property development and commercialisation to create long-term value for customers and shareholders.

Latest **Hydrix Limited** investor updates: www.hydrixltd.com.

Discover **Hydrix Medical** remote cardiac monitoring: www.hydrixmedical.com

Explore **Hydrix Services:** www.hydrix.com and on LinkedIn.

Learn about **Hydrix Defence:** Investor Presentation.

About Hydrix Medical

Hydrix Medical is committed to bringing the world's best cardiovascular technologies to market. We specialise in sourcing and distributing breakthrough, technology-rich products that support patients and healthcare professionals in addressing cardiovascular disease. The solutions we offer are carefully selected from leading global innovators and represent the latest in diagnostic, treatment and disease management capabilities. www.hydrixmedical.com.

About Implicity

Implicity is a leader in remote patient monitoring and cardiac data management solutions. Its remote monitoring and research platform is used by Independent Diagnostic Testing Facilities and cardiac electrophysiology centres to deliver better, high-quality care for their patients with Cardiac Implantable Electronic Devices. Implicity streamlines the management of a patient's clinical situation, enhancing efficiency and clarity for healthcare providers.

Implicity's platform aggregates, normalises, and standardises data from any implantable cardiac device across all manufacturers. This integration particularly benefits many heart failure patients who rely on CIEDs. Patients receive personalised support tailored to their specific needs, directly contributing to an improved quality of life from the comfort and safety of their homes.

Furthermore, Implicity carries out R&D on AI-based algorithms aiming at improving patient care and serving the future of preventive medicine. www.implicity.com.

About National Heart Centre Singapore (NHCS)

National Heart Centre Singapore is Singapore's national and regional referral centre for cardiovascular diseases and is a member of SingHealth, Singapore's largest healthcare group. NHCS is recognised as a leader in cardiovascular care, research and education throughout Asia . SingHealth offers a complete range of multi-disciplinary and integrated medical care. www.nhcs.com.sg.